We are live on ! Find out more
ERNA icon

Ernexa Therapeutics

11 hedge funds and large institutions have $712K invested in Ernexa Therapeutics in 2024 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 2 increasing their positions, 1 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 1

0.35% less ownership

Funds ownership: 7.56% → 7.21% (-0.35%)

15% less funds holding

Funds holding: 13 → 11 (-2)

67% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 3

90% less capital inflows, than outflows

Capital inflows: $5.26K | Capital outflows: $52.5K

Holders
11
Holders Change
-2
Holders Change %
-15.38%
% of All Funds
0.16%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
2
Reduced
1
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

ERNA Hedge Fund Activity: Q2 2024 in Review

11 of the 6,946 institutional investors tracked by Wall St. Rank reported a position in Ernexa Therapeutics (ERNA) for Q2 2024, worth a combined $712K — down 27% from $982K a quarter earlier.

Sellers outnumbered buyers: 3 funds closed out of ERNA and 1 opened new positions — a net loss of 2 holders — while 1 trimmed existing stakes and 2 added.

The largest buyer was Geode Capital Management, adding an estimated $2.26K. The largest seller was Citadel Advisors, exiting entirely with an estimated $24.1K sold.

  • 11 institutional investors held Ernexa Therapeutics (ERNA) as of Q2 2024, down from 13 in Q1 2024.
  • Funds reported $712K of Ernexa Therapeutics stock for Q2 2024, down 27% quarter-over-quarter.
  • 1 fund opened new Ernexa Therapeutics positions in Q2 2024 and 3 closed out, a net change of -2 holders.
  • The largest Ernexa Therapeutics buyer in Q2 2024 was Geode Capital Management, an estimated $2.26K added.
  • The largest Ernexa Therapeutics seller in Q2 2024 was Citadel Advisors, an estimated $24.1K sold.

Based on aggregated 13F filings for Q2 2024.